 | Up a level |
Article
Hill, Rebecca M, Kuijper, Sanne, Lindsey, Janet C, Petrie, Kevin, Schwalbe, Ed C, Barker, Karen, Boult, Jessica K R, Williamson, Daniel, Ahmad, Zai, Hallsworth, Albert, Ryan, Sarra L, Poon, Evon, Robinson, Simon P, Ruddle, Ruth, Raynaud, Florence I, Howell, Louise, Kwok, Colin, Joshi, Abhijit, Nicholson, Sarah Leigh, Crosier, Stephen, Ellison, David W, Wharton, Stephen B, Robson, Keith, Michalski, Antony, Hargrave, Darren, Jacques, Thomas S, Pizer, Barry, Bailey, Simon, Swartling, Fredrik J, Weiss, William A, Chesler, Louis and Clifford, Steven C (2015) Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer cell, 27 (1). pp. 72-84. ISSN 1878-3686
Hill, Rebecca M., Kuijper, Sanne, Lindsey, Janet, Schwalbe, Ed C., Barker, Karen, Boult, Jessica, Williamson, Daniel, Ahmad, Zai, Hallsworth, Albert, Ryan, Sarra, Poon, Evon, Robinson, Simon, Ruddle, Ruth, Raynaud, Florence, Howell, Louise, Kwok, Colin, Joshi, Abhijit, Nicholson, Sarah, Crosier, Stephen, Wharton, Stephen, Jacques, Tom, Robson, Keith, Michalski, Antony, Hargrave, Darren, Pizer, Barry, Bailey, Simon, Swartling, Fredrik J., Petrie, Kevin, Weiss, William A., Chesler, Louis and Clifford, Steve (2014) Abstract LB-201: MYC and TP53 defects interact at medulloblastoma relapse to define rapidly progressive disease and can be targeted therapeutically. Cancer Research, 74 (19_Sup). LB-201. ISSN 0008-5472
Hill, Rebecca M, Kuijper, Sanne, Lindsey, Janet C, Petrie, Kevin, Schwalbe, Ed C, Barker, Karen, Boult, Jessica K R, Williamson, Daniel, Ahmad, Zai, Hallsworth, Albert, Ryan, Sarra L, Poon, Evon, Robinson, Simon P, Ruddle, Ruth, Raynaud, Florence I, Howell, Louise, Kwok, Colin, Joshi, Abhijit, Nicholson, Sarah Leigh, Crosier, Stephen, Wharton, Stephen B, Robson, Keith, Michalski, Antony, Hargrave, Darren, Jacques, Thomas S, Pizer, Barry, Bailey, Simon, Swartling, Fredrik J, Weiss, William A, Chesler, Louis and Clifford, Steven C (2014) Abstract MB-013: MYC and TP53 defects interact at medulloblastoma relapse to define rapidly progressive disease and can be targeted therapeutically. Neuro-Oncology, 16 (Sup 1). i74-i74. ISSN 1522-8517